ARCA Hero Image
About ARCA

Our Focus

ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA’s lead development program is intended to be a direct implementation of those ideas. Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF). ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first…[more]

About ARCA

Our Focus

ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA’s lead development program is intended to be a direct implementation of those ideas. Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF). ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first…[more]

Management

people-bristow-cutfade

Michael R. Bristow, M.D., Ph.D.

President & Chief Executive Officer

Dr. Bristow joined ARCA as one of ARCA’s founders in September 2004, and served as Chairman and Chief Science and...[+more]

people-keuer-cutfade

Thomas A. Keuer

Chief Operating Officer

Mr. Keuer was appointed to his current position as Chief Operating Officer in December 2014. He joined ARCA in October...[+more]

people-brian-cutfade

Brian Selby

Vice President Finance & Chief Accounting Officer

Mr. Selby has held the position of Vice President, Finance and Chief Accounting Officer since December 2014. He was the...[+more]

people-ozeroff-cutfade

Christopher D. Ozeroff

Senior Vice President & General Counsel

Mr. Ozeroff has been ARCA’s Senior Vice President and General Counsel since September 2004. From August 1999, Mr. Ozeroff was...[+more]

Board of Directors

Robert E. Conway

Chairman

Mr. Conway has over 30 years of executive leadership experience in the pharmaceutical and biotechnology industries. From 1999 to 2012,...[+more]

Michael R. Bristow, M.D., Ph.D.

Chief Executive Officer

Dr. Bristow joined ARCA as one of ARCA’s founders in September 2004, and served as Chairman and Chief Science and...[+more]

Linda Grais, M.D.

Director

Dr. Grais has served as a member of ARCA’s board of directors since May 2007. She is a former Partner...[+more]

Anders Hove M.D.

Director

Dr. Hove was most recently a general partner of Venrock Associates (“Venrock”), a venture capital firm, which he joined in...[+more]

Dan Mitchell

Director

Dan Mitchell was appointed to the Company’s Board of Directors in February of 2014. Mr. Mitchell founded and is a...[+more]

Raymond L. Woosley, M.D., Ph.D.

Director

Dr. Woosley, age 70, was elected to the ARCA Board of Directors in July 2013. Dr. Woosley is currently President...[+more]